![](/img/cover-not-exists.png)
Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point
Brown, David M., Chen, Eric, Mariani, Angeline, Major, James C.Volume:
120
Language:
english
Journal:
Ophthalmology
DOI:
10.1016/j.ophtha.2012.08.008
Date:
February, 2013
File:
PDF, 1.33 MB
english, 2013